MAY 30, 2017 9:00 AM PDT

Protein and Cell Analysis Education Series featuring the Antibody Validation Forum

  • CEO, Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada; International Working Group for Antibody Validation (IWGAV) member
      Aled Edwards is the founding CEO of the Structural Genomics Consortium (SGC), an international public-private partnership that generates open-sourceresearch tools to support basic science and drug discovery. With 300 scientists within its laboratories in Campinas, Chapel Hill, Frankfurt, Oxford, Stockholm, and Toronto, the SGC has contributed ~15% of all the available structural information for human proteins in the public domain, and has generated chemical probes and validated antibodies that have helped identify new targets for cancer drug discovery. Al was also the founder of Affinium Pharmaceuticals, which was purchased by Debiopharm for its antibiotic program, as well as the Structure-guided Drug Discovery Coalition, a drug discovery partnership currently supported by the Gates Foundation. He is an advisor to Welcome and to a number of governments on Open Science. Al did his undergraduate and graduate work at McGill University and his postdoctoral work at Stanford University with Roger Kornberg, where he initiated the structural biology of RNA polymerase II. He is currently on faculty at the University of Toronto, the University of Oxford, and McGill University.
    • Director of Strategy and Partnering for Antibodies and Immunoassay, Biosciences Division, Thermo Fisher Scientific
        Matt is currently the Director of Strategy and Partnering for the Antibodies and Immunoassay business at Thermo Fisher Scientific. Previous to this role, he served as the head of research and development. He has more than 20 years of experience developing and validating antibodies for life science research. He started his career in custom antibody development serving both academic and pharmaceutical customers delivering more than 10,000 customized antibodies. Matt has also worked extensively in immunoassay development and advancing new platforms for the quantitative detection of proteins.
      • Scientific Lead, Neuroscience Information Framework, Center for Research in Biological Systems, University of California at San Diego, San Diego, California, USA; Founder and CEO of SciCrunc
          Anita is focused on establishing the means for communicating and utilizing the internet for effective scientific communication and discovery. She serves as the lead for the Resource Identification Initiative, a FORCE11, the Future of Research Communications and e-Scholarship, group dedicated to transforming scholarly communication. FORCE was one of the drivers in open access movement and continues to drive innovation in understanding principles behind sharing and utilization of data, software and the role for identifiers. In addition, she is working in the area of knowledge representation in genomics for both Celera (coding the completed human genome into PANTHER) and Human Longevity (gene variants VaNDa), and the neurosciences within the Neuroscience Information Framework (NIF), funded by the Blueprint for Neuroscience a pan-NIH initiative. She is also the scientific lead of the NIF project, the largest source of neuroscience data and tools on the web. The NIF framework has been extended to develop data portals for NIDDK (dkNET) and the RRID community portal, where authors are able to improve their manuscripts prior to submission for publication. This has led to the launching of a new company (SciCrunch) which is focused on improving interactions between academic scientists and the business community, both of which are major stakeholders and contributors in driving science forward.
        • Professor of Oncology, and Director, Flow and Image Cytometry Facility, Roswell Park Cancer Institute, Buffalo, NY, USA; Associate Professor of Pathology, State University of New York at Buff
            Paul joined the staff of Roswell Park Cancer Institute (RPCI) in 2003, as Director of the Flow and Image Cytometry Resource. He is an Associate Professor in the Department of Cancer Prevention and Pathology and a Member of the Immunology Program. He is also an Associate Professor in the Departments of Pathology and of Biotechnical and Clinical Laboratory Sciences, University at Buffalo (SUNY). He earned his doctoral degree in Immunology at the Medical College of Pennsylvania (Drexel University), Philadelphia, PA, and completed a postdoctoral fellowship in Immunology at Dartmouth Medical School, Hanover, NH in 1996 and remained at Dartmouth as an Assistant Professor until joining Roswell Park. Paul is an active member of the International Society for Analytical Cytometry (ISAC) and the International Clinical Cytometry Society. He has authored or co-authored more than 85 peer reviewed journal articles or book chapters and has over 190 Abstracts. He is also Director of the Annual Clinical Flow Cytometry course.
          • Senior R&D Manager, Mass Spectrometry Reagents, Protein and Cell Analysis, Biosciences Division, Thermo Scientific
              John is a Senior R&D Manager at Thermo Scientific where he manages the development of new reagents and kits for protein mass spectrometry research. John has an undergraduate degree in Biochemistry and Computer Science, and a PhD in Pharmacology from the University of Washington. John managed a bioinformatics group at Pfizer and a proteomics group at Abbott before joining Thermo Fisher Scientific in 2007. Since that time, John has led the development of new MS standards and calibrants, protein sample preparation reagents, and reagents for quantitative proteomic analysis, including Tandem Mass Tag reagents.
            • Vice President of R&D for Protein and Cell Analysis, and Antibodies and Immunoassays, Biosciences Division, Thermo Fisher Scientific
                Christoph is currently the Vice President of R&D for Protein and Cell Analysis and Antibody and Immunoassay groups at Thermo Fisher Scientific. In the last 20+ years he has extensive industrial experience including serving as Vice President of R&D at BD Biosciences; as Global Technology Leader at the General Electric Global Research Center where he built the Global Technology Organization for Biosciences; as Vice President of Research within the Discovery Group at Amersham Biosciences; as Chief Scientific Officer at Xantos Biomedicine; and as Senior Scientist and Director of Technology Management for Boehringer Mannheim, Germany/Roche Diagnostics division, USA. Christoph received his doctorate in Molecular Cell Biology and Protein Chemistry from the University of Munich and postdoctoral training in Immunology, also at University of Munich.


              Addressing the antibody reproducibility crisis: A panel discussion with key scientific leaders


              Reproducibility and antibody validation standards are two significant challenges facing scientific researchers today.  To address these issues, Thermo Fisher Scientific—a leading producer of antibodies— organized and supported a group of leading researchers from several global institutions. This International Working Group for Antibody Validation (IWGAV) brainstormed and developed a set of proposed standards to optimize antibody validation methods with a specific emphasis on antibody specificity verification.  As a follow up, in fall 2016, the Global Biological Standards Institute (GBSI) hosted a meeting attended by several IWGAV members and representatives from antibody producers, pharmaceutical companies and leading academic research labs. Attendees reviewed and validated the IWGAV proposed standards and discussed strategies designed to implement these standards across the industry.  


              In this event, Thermo Fisher Scientific will host a live, virtual round table discussion in which representative IWGAV members and others from the research community will participate in a dialogue about antibody validation standards and practices, with the goal of finding consensus for how to further methods for verifying antibodies used for common laboratory techniques—such as western blotting, ELISA, immunohistochemistry, immunofluorescence. The panel will also discuss how these new standards may be adapted to validate antibodies intended for flow cytometry.



              SESSION 2-WEBINAR

              Time: 10:00 AM PDT

              Antibody validation with immunoprecipitation/mass spectrometry and orthogonal methods (Login here)

              Speaker: John Rogers, PhD, Thermo Fisher Scientific


              SESSION 3-WEBINAR

              Time: 11:00 AM PDT

              Super Bright antibody conjugates for flow cytometry—Bright polymer dyes for the violet laser (Login here)

              Speaker: Castle Funatake, PhD, Thermo Fisher Scientific


              SESSION 4-WEBINAR

              Time: 12:00 PM PDT

              Chemiluminescent western blot detection: Bright and bold detection no matter how scarce your target (Login here)

              Speaker: Emily Halbrader, Thermo Fisher Scientific


              SESSION 5-WEBINAR

              Time: 1:00 PM PDT

              The new generation in immunoassays (Login here)

              Speaker: David Bourdon, PhD, Thermo Fisher Scientific


              Show Resources
              You May Also Like
              MAY 11, 2021 10:00 AM PDT
              C.E. CREDITS
              MAY 11, 2021 10:00 AM PDT
              Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
              JUN 09, 2021 7:00 AM PDT
              Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
              C.E. CREDITS
              JUN 09, 2021 7:00 AM PDT
              Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
              Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
              MAR 16, 2021 10:00 AM PDT
              C.E. CREDITS
              MAR 16, 2021 10:00 AM PDT
              Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
              APR 01, 2021 8:00 AM PDT
              C.E. CREDITS
              APR 01, 2021 8:00 AM PDT
              Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
              NOV 18, 2020 8:00 AM PST
              C.E. CREDITS
              NOV 18, 2020 8:00 AM PST
              DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
              DEC 02, 2020 8:00 AM PST
              C.E. CREDITS
              DEC 02, 2020 8:00 AM PST
              DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
              MAY 30, 2017 9:00 AM PDT

              Protein and Cell Analysis Education Series featuring the Antibody Validation Forum



              Molecular Biology

              Cell Biology


              Cancer Research


              Cell Culture



              Molecular Diagnostics

              Laboratory Testing

              Clinical Research

              Clinical Diagnostics

              Assay Development

              Cancer Therapeutics


              North America53%



              South America4%



              Registration Source

              Website Visitors100%

              Job Title



              Facility/Department Manager14%

              Research Scientist13%



              Post Doc5%

              Medical Doctor/Specialist4%

              Lab Management4%

              Medical Laboratory Technician3%

              Clinical Laboratory Scientist2%




              Academic Institution12%

              Biotech Company9%

              Research Institute5%

              Life Science Company4%


              Clinical Laboratory2%


              Pharmaceutical Company2%

              Ambulatory Care2%

              Contract Research Organization (Cro)1%

              Industrial Company1%

              Medical Center1%

              Medical School1%

              Non-Profit Organization1%


              Show Resources
              Loading Comments...
              Show Resources
              • See more